- cafead   Aug 12, 2021 at 12:23: AM
via Real-world oncology data, which is increasingly being touted as a potential basis for regulatory and reimbursement decisions, tends to be of poor quality and may overstate the survival benefits of cancer drugs, according to a new analysis.
article source
article source